How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit. by Kim, Lois G et al.
1 
 
 
How do primary care doctors in England and Wales code and manage people with chronic kidney 
disease? 
Results from the National Chronic Kidney Disease Audit 
 
Lois G Kim1,2, Faye Cleary1, David C Wheeler3, Ben Caplin3, Dorothea Nitsch1, Sally A Hull4 
On behalf of the UK National Chronic Kidney Disease Audit 
 
1 Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology and Population 
Health, London School of Hygiene and Tropical Medicine, Keppel St, London. WC1E 7HT.  
2 Cambridge Centre for Health Services Research, Department of Public Health and Primary Care, 
University of Cambridge, School of Clinical Medicine, Cambridge. CB2 0SR.  
3 Clinical Effectiveness Group, Centre for Primary Care and Public Health, Queen Mary University of 
London, Yvonne Carter Building, 58 Turner St, London. E1 2AB. 
4 Centre for Nephrology, UCL Medical School. Rowland Hill St, London. NW3 2PF.  
 
 
 
 
Corresponding author:  
Lois G Kim, 
Cambridge Centre for Health Services Research, 
 Department of Public Health and Primary Care,  
University of Cambridge,  
School of Clinical Medicine,  
Cambridge.  
CB2 0SR. 
 
T. 01223 761762 
lois.kim@lshtm.ac.uk 
2 
 
 
Keywords: audit, chronic kidney disease, coding, management, primary care 
Summary:   
In the UK, primary care records are electronic and require doctors to ascribe disease codes to 
facilitate efficient care and appropriate prescribing. The National CKD Audit assessed how many 
people in England and Wales with evidence for CKD stages 3-5 based on biochemical data were 
coded with CKD by primary care doctors. Patients who had biochemical evidence of CKD but were 
not coded as such were less well managed. In summary, further incentivising coding for CKD in UK 
primary care may improve outcomes for patients.  
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Abstract 
 
Background 
In the UK, primary care records are electronic and require doctors to ascribe disease codes to direct 
care plans and facilitate safe prescribing. We investigate factors associated with coding of chronic 
kidney disease (CKD) in patients with reduced kidney function and the impact this has on patient 
management.  
Methods 
We identified patients meeting biochemical criteria for CKD (two eGFRs <60ml/min/1.73m2 taken 
>90 days apart) from 1039 GP practices in a UK audit. Clustered logistic regression was used to 
identify factors associated with coding for CKD and improvement in coding as a result of the audit 
process. We investigated the relationship between coding and five interventions recommended for 
CKD: achieving blood pressure targets, proteinuria testing, statin prescription, and flu and 
pneumococcal vaccination.  
Results 
Of 256,000 patients with biochemical CKD, 30% did not have a GP CKD code. Males, older patients, 
those with more severe CKD, diabetes, hypertension, or those prescribed statins were more likely to 
have a CKD code. Amongst those with continued biochemical CKD following audit, these same 
characteristics increased the odds of improved coding. Patients without any kidney diagnosis were 
less likely to receive optimal care than those coded for CKD (e.g. OR for meeting blood pressure 
target 0.78, 95% CI 0.76 to 0.79).  
Conclusion 
Older age, male sex, diabetes and hypertension are associated with coding for those with 
biochemical CKD. CKD coding is associated with receiving key primary care interventions 
recommended for CKD. Increased efforts to incentivise CKD coding may improve outcomes for CKD 
patients. 
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Introduction 
Chronic kidney disease (CKD) has an estimated prevalence in the UK of around 5-7%1, 2, based on 
creatinine measurements for stage 3-5 disease. The majority of CKD patients are diagnosed and 
managed by primary care physicians, rather than kidney specialists in secondary care settings. Early 
identification of people with CKD in primary care, particularly among populations with risk factors 
such as diabetes and hypertension, enables early management of high blood pressure and 
correction of adverse lifestyle factors. Progression of CKD can be delayed by such interventions3, and 
the implementation of these interventions can be improved by use of quality improvement tools in 
primary care4.  
 
In the UK, primary care health records are computerised, with each condition given a diagnostic 
“Read code” to enable more systematic patient management and appropriate prescribing. The UK 
Quality and Outcomes Framework (QOF)8  is an ongoing pay for performance system which 
incentivises aspects of primary care delivery. Coding for CKD based on two eGFR measurements 
below 60ml/min/1.73m2 within 90 days has been incentivised in the QOF; however, there is 
evidence to suggest that this system does not capture all CKD cases meeting diagnostic criteria. It 
has been reported that only 55-70% of patients with biochemical evidence of CKD (stages 3-5) have 
an appropriate Read code in GP practice databases5-7. Practice-level prevalence of coded CKD (as 
captured in QOF) is positively associated with practice prevalence of diabetes, cardiovascular 
disease, and negatively associated with social deprivation9. The extent of this lack of coding varies 
widely by GP practice, even after accounting for practice-level differences in risk factors such as 
diabetes6. QOF registers are also subject to error relating to cases coded as CKD in the absence of 
biochemical evidence; recent data suggested that 11% of cases on QOF registers do not fulfil 
biochemical testing criteria, rising to 36% amongst those with black ethnicity1. It has further been 
shown that appropriate coding of CKD in the primary care electronic record may be associated with 
improved blood pressure management and urinary albuminuria testing, in comparison to those with 
uncoded CKD5.  
 
The National Chronic Kidney Disease Audit6 (NCKDA) was set up to audit the testing, identification 
and management of CKD in primary care in the UK. The audit capitalised on the existence of 
computerised practice records, and used an automated extraction tool that directly extracted data 
from the electronic health record with automatic encrypted upload to a central data safe haven. The 
first round of data collection (round 1) provided an initial snapshot of the above outcomes for the 
practices enrolled in the audit. Practices were encouraged to make use of the electronic quality 
improvement (QI) tools for CKD which had been developed by the NCKDA team in collaboration with 
Informatica Systems as an integral component of the audit. The QI tools provided practice lists of 
people with risk factors who may need testing for CKD, people who may require CKD coding or 
coding removal, and prompts to support the management of those with coded CKD. In addition, 
consultation prompts alerting clinicians to people with uncoded CKD could be activated1. A second 
extraction of data was made (round 2) at least 90 days after round 1, to ascertain the impact of the 
QI aspect of the audit process.  
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We used individual patient data from the NCKDA to investigate the associations between individual 
patient characteristics and coding for CKD, amongst those with biochemical evidence of CKD based 
on creatinine measurements. We further sought to identify the characteristics associated with 
improvements in coding status at round 2. Amongst patients with biochemical evidence of CKD, we 
then investigated the relationship between coding and five key markers of primary care 
management of CKD10: (1) meeting blood pressure targets, (2) being offered statins for 
cardiovascular disease (CVD) prevention, (3) receipt of urinary albumin-to-creatinine ratio (ACR) or 
protein-to-creatinine ratio (PCR) testing, (4) receipt of flu vaccine, and (5) receipt of pneumococcal 
vaccine (for those with CKD stage 4-5 disease).  
 
This work will help identify whether there are population sub-groups for whom coding for CKD 
requires improvement, and whether these same characteristics are associated with lack of coding 
improvement or receipt of primary care interventions aimed at improving patient outcomes. 
 
Methods 
Data source and study population 
All practices in the England and Wales who were current users of the Informatica Audit Plus software 
were invited to participate in NCKDA between March 2015 and July 2016). NCKDA round 1 data were 
collected from all GPs in 1039 GP practices representing an underlying population of 8.24m over 18-
year-olds in England and Wales. Coverage in England and Wales differed substantially as a result of 
technical difficulties and differential use of the software used to extract data for the NCKDA1; final 
coverage was approximately 76% of practices in Wales and 9% of practices in England. All Welsh 
practices had Audit Plus installed (funded by the National Health Service in Wales) whilst in England, 
practices actively purchased Informatica audit plus software to support better disease 
management1. Data on CKD coding, eGFR test results, and relating to CKD management were 
extracted for all patients with risk factor coding for CKD at least one year prior to data extract. A full 
list of risk factor codes and full details regarding the study population is available elsewhere1. 
Practices received an email feedback about the prevalence of biochemical, coded and uncoded CKD 
suggesting that they might use the QI software to improve coding.  
Round 2 data were collected from 948 of these practices, with a median of 8 months from round 1 
(range 3 to 20 months). Figure 1 shows patient progress from round 1 to round 2 by coding status. 
65,661 patients with uncoded CKD at round 1 (i.e. no code for stage 3-5 CKD, but with biochemical 
evidence for CKD) for whom round 2 data confirming biochemical CKD were available, were included 
in an analysis of coding improvement. 
Information about referrals to secondary care was available through (i) extraction of out-patient 
referral codes collected at round 1 from the GP record and (ii) linkage to out-patient records from 
Hospital Episode Statistics (HES) for England (data collected for the period 01/04/12 to 30/06/16) 
and NHS Wales Informatics Statistics (NWIS) (01/01/12 to 30/06/16). 
 
Outcomes 
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Coding 
Coding status for CKD (defined by the presence of a code for stage 3-5 CKD ) was analysed for 
256,433 patients with biochemical evidence of CKD (two MDRD-IDMS eGFR measurements 
<60ml/min/1.73m2 at least 90 days apart). MDRD-IDMS measurements incorporating the ethnicity 
adjustment were derived from creatinine measurements and used for this analysis, as the majority 
of labs in the UK do not report the CKD-EPI eGFR.  
 
 
Coding improvement 
Amongst patients with uncoded CKD at round 1 and for whom round 2 data confirm biochemical 
CKD, coding improvers were defined as those who had a code for stage 3-5 CKD at round 2. 
 
Referrals to secondary care 
Referral to secondary care is defined as any nephrologist referral code collected at round 1 from the 
GP records or any nephrologist out-patient clinic code held in the HES database (see Appendix).  
 
Primary care management of CKD 
(a) Blood pressure management 
Patients were considered to have met blood pressure targets if they had blood pressure 
measurements taken in the previous year and either (i) systolic blood pressure <130mmHg and 
diastolic blood pressure <80mmHg (for those with diabetes or proteinuria defined as last 
ACR≥70mg/mmol or last PCR ≥100mg/mmol) or (ii) systolic blood pressure <140mmHg and diastolic 
blood pressure <90mmHg (for everyone else). Those with blood pressure measurements taken more 
than one year earlier were not included as meeting targets, regardless of measurement. Only the 
single most recent blood pressure measurement was available from the GP record. 
 
(b)  Statins 
As part of CVD prevention strategy, statin therapy  is recommended for all individuals with CKD stage 
3-511. We report here for individuals for whom there was any previous recording of statin 
prescription collected at round 1 from the GP record.  
 
(c) Proteinuria testing 
It is recommended that testing for proteinuria is carried out at least once a year for all individuals 
with CKD stage 3-5 (increasing to 4 times a year for those at stage 5)10, 11. Proteinuria testing was 
considered as having been undertaken if patients had had an albumin-to-creatinine ratio (ACR) or 
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protein-to-creatinine ratio (PCR) test collected at round 1 that was from (i) the previous year or (ii) 
the previous two years, to provide some insight into the extent of deviation from testing guidelines. 
 
(d) Flu vaccination 
Guidelines state that all individuals with CKD stage 3-5 should be offered an annual flu vaccination 
unless contraindicated10. We report the percentage of patients receiving this vaccination in the 
previous year.  
 
(e) Pneumococcal vaccination 
For individuals with CKD stage 4-5, it is additionally recommended that pneumococcal vaccination is 
administered unless contraindicated, and that individuals are offered re-vaccination within five 
years10. We report the percentage of patients with stage 4-5 disease receiving this vaccination in the 
previous five years.  
 
Amongst those with uncoded CKD, results are presented separately for those with and without a 
urological or renal diagnostic disorder code (a full list of corresponding read codes is available 
elsewhere1). 
 
Predictors of coding and coding improvement 
The following characteristics were considered as potentially being associated with coding and/or 
coding improvement:  
(i) Age: categorised in 10-year age-bands (plus <50 and 90+ groups).  
(ii) Index of multiple deprivation (IMD): categorised in approximate quintiles of the distribution 
for the study population, plus an additional category for those with missing IMD (these 
are all from Welsh practices; 93% of Welsh practices did not have any IMD data 
available).  
(iii) Last known CKD stage: defined by categorising the last known eGFR measurement using 
standard definitions10: stage 3a (eGFR 46-59ml/min/1.73m2), stage 3b (eGFR 31-
45ml/min/1.73m2), stage 4 (eGFR 16-30ml/min/1.73m2) and stage 5 
(eGFR<15ml/min/1.73m2).  
(iv) Diabetes: defined as any previously recorded diagnosis for diabetes (incentivised by QOF). 
(v) Hypertension: defined as any previously recorded date for hypertension diagnosis 
(incentivised by QOF).  
(vi) Statin prescription: defined as any previously recorded date on which statins were 
prescribed. 
(vii) Country:  indicator for Wales or England. 
 
Statistical methods 
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Population-averaged logistic GEE models were fitted for having coded CKD (amongst those with 
biochemical CKD at round 1) and for coding improvement (amongst those with uncoded biochemical 
CKD at round 1 and biochemical CKD at round 2), allowing for clustering of patients within practices.  
Use of five interventions for CKD was summarised amongst those with biochemical CKD according to 
CKD and renal disorder coding status. Odds ratios comparing the coding groups for each of these 
management outcomes were estimated using population-averaged clustered logistic GEE models 
adjusted for IMD group, sex, age group, country, last known CKD stage, diabetes, hypertension, CVD 
and statins (except for statins outcome).  
 
 
 
Results 
 
Predictors of coding for CKD 
A breakdown of coding status by key characteristics is given in Table 1 for the 256,433 patients with 
stage 3-5 biochemical CKD, among which 78,156 (30%) did not have a read code for CKD. There was 
considerable inter-practice variation in the proportion of biochemical CKD cases that were coded, 
ranging from 4% to 100%.  
 
Being male, being older, having later stage CKD, lower IMD (more deprived), diabetes, hypertension 
and being offered statins were all associated with increased odds of coding in unadjusted analyses. 
In a mutually adjusted analysis, all these associations remained except for IMD (Table 1). Belonging 
to an English practice rather than a Welsh practice also seemed to increase the odds of coding in 
both the unadjusted and adjusted analyses. There was evidence that the difference between males 
and females was only present in Wales (multivariable OR for males in Wales 1.11, 95% CI 1.07 to 
1.14; in England, multivariable OR 1.01, 95% CI 0.99 to 1.04; p-value for interaction <0.0005).  
 Around half of those with uncoded stage 5 CKD (164 / 317) also had a renal disorder code (Table 2). 
Of the 153 who did not, 45 had either a dialysis or a transplant code, and a further 70 had a 
nephrologist referral code (either in the audit data or HES data). This left 38 / 3254 (1%) of patients 
with biochemical evidence of stage 5 CKD who were not coded for CKD, had no other renal code and 
who also had no referral, dialysis or transplant code.  
 
Predictors of coding improvement at round 2 
Amongst those with uncoded biochemical CKD at round 1 who also had biochemical evidence of CKD 
at round 2, 5,211 patients (out of 54,000; 9.7%) were found to have been coded at round 2 (Table 3).  
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After adjusting for other factors, those aged under 60 had a 15-20% reduction in odds of coding 
improvement compared to those aged 60+, although those aged 90+ also had a 15% reduction in 
odds of coding improvement compared to those aged 60-69 (OR 0.86 (0.79, 0.95)) (Table 3). Those 
with CKD stage 3b-5 all had a 1.5 to 2-fold increase in the odds of coding compared to those with 
biochemical evidence for CKD stage 3a. Furthermore, there was evidence of higher odds of coding 
improvement amongst males and those with diabetes, hypertension and on statins. There was no 
evidence of a difference in improvement by IMD.  
 
Associations of coding with CKD management  
Receipt of all primary care management interventions was highest in those who were coded for CKD 
(Table 4). The odds of receiving each intervention were greatest in those with coded CKD; the odds 
of intervention were comparatively reduced amongst those with uncoded CKD and a renal disorder 
code (except for statins, where the adjusted odds were similar to those with coded CKD), and 
reduced even further for those with uncoded CKD and no renal disorder code. 
Blood pressure targets had only been met in the previous year in around 50% of patients with coded 
CKD; the odds of meeting the target were even lower in those with uncoded CKD, with a 15% 
reduction in those with a renal code and a 20% reduction in those without a renal disease code. 
Proteinuria testing was also low at around 50% of coded CKD patients in the previous year; this was 
considerably lower in those with uncoded CKD, with around a 50% and 80% reduction in odds for 
those with and without renal codes respectively. Around 70% of those patients with coded CKD had 
been offered a statin at some time in the past, with substantially reduced odds for those with 
uncoded CKD and no renal disease code. There was around a 20% reduction in odds of receiving 
both vaccinations for those with uncoded CKD and a renal code compared to those with coded CKD, 
and a 25% reduction in odds for those with uncoded CKD and no renal code.  
 
Referrals to secondary care 
Referrals recorded on either the GP record or hospital episode statistics (HES) databases accounted 
for 27.9% of those with uncoded CKD at round 1 with a renal code, but only 5.3% of those with 
uncoded CKD and no renal code (compared to 19.0% of those with coded CKD). 
 
Discussion 
Main findings 
Younger patients, females, and those without major co-morbidities (diabetes, hypertension) who 
have biochemical evidence of CKD are least likely to have a CKD (3-5) code in their primary care 
record. Patients with biochemical CKD without a CKD code were less likely to be offered a statin, 
receive flu and pneumococcal vaccination, have their blood pressure controlled to target or have 
undergone proteinuria testing. Those who have biochemical evidence of CKD and a renal code were 
more likely to have received some interventions, but not to the same level as people with 
biochemical CKD who were coded.  
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Main findings in context 
Among the 256,433 cases with biochemical evidence of CKD at round 1 of the national CKD audit, 
only 70% (178,277 / 256,433) are included on the QOF register as CKD stage 3-5. This compares to 
72% reported by Jain et al5 in a sample of similar size from 2005-9. Although broadly similar, some of 
the difference could be explained by the definitions of biochemical CKD used (we use two eGFRs at 
least three months apart, versus their two measurements seven days apart), and our use of re-
calculated eGFRs. 
Amongst those patients with biochemical evidence of CKD, males, older patients, those with lower 
eGFR (more severe CKD stage), diabetes, hypertension, receiving statins and in English practices had 
increased odds of being coded for CKD. Another study previously reported similar relationships with 
sex and co-morbidities, but not with age12. Our results suggest that even for patients with the same 
CKD stage and co-morbidities, younger patients have reduced odds of coding compared to older 
patients. Furthermore, we have shown that these same characteristics (except country) were 
associated with coding improvement following audit amongst those patients with uncoded 
biochemical CKD at round 1 who still had evidence of biochemical CKD at round 2. Although others 
have demonstrated that quality improvement tools can be useful in improving intervention 
outcomes13, such studies have taken a more direct approach to improve specific interventions such 
as blood pressure control rather than through coding improvements, which may be more wide-
reaching.   
Our findings on management interventions for patients with coded CKD in primary care are also 
broadly similar to those reported elsewhere14, 15, but we have also demonstrated the positive 
relationship between coding and patient management. 
 
Interpretation and implication 
There are many reasons why an individual with biochemical evidence of CKD may not have a 
corresponding code, including uncertainty about guidelines for testing and diagnosis and concern 
about medicalising a natural aging process15. However, the relevance of the absence of coding lies in 
its potential impact on a range of patient measures in primary care. Here, this is substantiated by the 
reported differences in the application of key management interventions between coded and 
uncoded groups with biochemical CKD. Amongst those with uncoded CKD, having a renal disorder 
code is associated with higher application of all these interventions, though not to the same level as 
those with a CKD code. We examined the possibility that the observed differences are, at least in 
part, due to differences in recording of these interventions and whether those with renal disorder 
codes may be managed in secondary, rather than primary care, with a corresponding lack of 
recording on GP databases. Investigation of referrals to secondary care suggests that although the 
difference in interventions in patients with coded CKD and those with uncoded CKD and a renal 
disorder may in part be explained by differences in referrals, there is no evidence that patients 
without a CKD or a renal disorder code are receiving interventions in secondary care. However, it is 
also possible that some referrals were not captured here for example, for joint specialist outpatient 
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clinics which may be coded under the non-nephrology speciality code in HES (e.g joint diabetic-renal 
specialist clinic, or joint urology-renal clinic).  
Our findings suggest that practices and local health authorities should take a more active approach 
to ensuring CKD coding and resultant patient review for those with CKD, and that implementation is 
encouraged using active quality improvement techniques. In the UK, this is of particular importance 
as the renal QOF indicators have now been retired16.  
 
Strengths and limitations 
We use data from a large, population-based study to investigate relationships between coding, 
patient characteristics and care. Although large and with good coverage of Welsh practices (76%), 
the study includes only 9% of English GP practices. It is likely that practices with higher ethnic 
minorities are under-represented in this sample (in England, the non-white population is around 
9.1%, compared to 4.4% in Wales17). Previous work has suggested that CKD prevalence varies across 
ethnic minorities18, but also that management outcomes may be reduced in these minority sub-
groups19. Furthermore, participating English practices had chosen to install the audit software and 
therefore are more likely to have an interest in quality improvement. In light of this, for England, the 
underlying proportion of uncoded biochemical CKD cases may be even higher than we report, and 
management outcomes may be lower in some or all of the groups of patients with CKD.  
Limitations of the audit include the use of routinely collected clinical data. There will inevitably be 
inaccuracies in the clinical dataset, and it is likely that there will be under-recording of at least some 
morbidities, however under-recording would mean that the GP also is not aware of the respective 
morbidity. The “missingness” in hypertension, diabetes and statin prescriptions is not known, since 
this would occur where there is an absence of a recorded date, making it indistinguishable from 
individuals without these events. However, as recording of hypertension and diabetes has been 
incentivised by QOF through a number of measures, there is little reason to assume that a majority 
of cases would have been missed.  
 
Conclusions 
Electronic quality improvement initiatives, which alert practitioners to uncoded CKD cases, with in-
consultation prompts and patient lists requiring action, produce a small but important improvement 
in coding. However, this improvement tends to be focussed on older patients and those with well-
established risk factors for CKD. Further efforts to improve coding for younger patients who have 
much to gain from regular CKD review, blood pressure and CVD risk management are needed. 
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Table 1  Coding for CKD by patient characteristics, amongst those with biochemical 
evidence of CKD 
 N with 
biochemical 
CKD at 
round 1 
% of these 
who are 
coded for 
CKD 
Univariable OR for 
coding (95% CI) 
Multivariable** OR 
for coding (95% CI) 
Sex 
     Female 
     Male 
 
152,194 
104,239 
 
68.8% 
70.6% 
 
1 
1.09 (1.06, 1.11) 
 
1 
1.04 (1.02, 1.07) 
Age 
     <50 
     50-59 
     60-69 
     70-79 
     80-89 
     90+ 
 
5,371 
12,612 
39,520 
82,776 
90,209 
25,945 
 
57.7% 
55.9% 
62.1% 
69.7% 
73.9% 
74.2% 
 
0.82 (0.77, 0.87) 
0.79 (0.76, 0.82) 
1 
1.38 (1.34, 1.42) 
1.69 (1.64, 1.75) 
1.72 (1.64, 1.80) 
 
0.82 (0.78, 0.88) 
0.86 (0.83, 0.89) 
1 
1.23 (1.20, 1.27) 
1.37 (1.32, 1.41) 
1.34 (1.28, 1.40) 
IMD$ 
     <10000 
     10000-14999 
     15000-19999 
     20000-24999 
     25000+ 
     Missing 
 
41,051 
28,079 
30,222 
31,815 
40,230 
85,036 
 
71.4% 
71.2% 
70.4% 
70.1% 
70.1% 
67.2% 
 
1 
0.98 (0.95, 1.02) 
0.95 (0.92, 0.99) 
0.94 (0.91, 0.97) 
0.95 (0.91, 0.99) 
0.86 (0.78, 0.95) 
 
1 
1.00 (0.97, 1.04) 
0.98 (0.94, 1.02) 
0.99 (0.95, 1.02) 
1.01 (0.97, 1.05) 
1.09 (0.96, 1.23) 
Last known CKD stage* 
     Stage 3a  
     Stage 3b  
     Stage 4  
     Stage 5  
 
 
160,100 
75,855 
17,224 
3,254 
 
 
60.8% 
82.5% 
89.7% 
90.3% 
 
 
1 
3.01 (2.90, 3.12) 
5.64 (5.25, 6.06) 
5.94 (5.22, 6.77) 
 
 
1 
2.71 (2.62, 2.80) 
5.03 (4.70, 5.38) 
5.81 (5.13, 6.58) 
Diabetes 
     No 
     Yes 
 
187,716 
68,717 
 
67.5% 
75.2% 
 
1 
1.45 (1.41, 1.49) 
 
1 
1.11 (1.08, 1.14) 
Hypertension 
     No 
     Yes 
 
74,817 
181,616 
 
59.2% 
73.8% 
 
1 
1.83 (1.79, 1.87) 
 
1 
 1.50 (1.47, 1.53) 
Statin offered 
     No 
     Yes 
 
84,885 
171,548 
 
62.0% 
73.3% 
 
1 
1.64 (1.60, 1.67) 
 
1 
1.38 (1.35, 1.40) 
Country 
     Wales 
     England 
 
85,308 
171,125 
 
67.1% 
70.7% 
 
1 
1.25 (1.12, 1.40) 
 
1 
1.42 (1.18, 1.71) 
* Based on last eGFR measurement. Stage 3a: eGFR 46-59ml/min/1.73m2; stage 3b: eGFR 31-
45ml/min/1.73m2; stage 4: eGFR 16-30ml/min/1.73m2; stage 5: eGFR<15ml/min/1.73m2 
** simultaneous adjustment for all characteristics in table 
$ Low IMD rank corresponds to higher deprivation
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Table 2  Percentage of coding for renal disorder by CKD coding status and stage, amongst 
those with biochemical evidence of CKD at round 1 of the National CKD Audit 
 
 CKD Coded CKD not coded 
Last known CKD 
stage* 
N % with renal 
disorder code 
N % with renal 
disorder code 
Stage 3a 97,352 13.7% 62,748 6.2% 
Stage 3b 62,543 19.3% 13,312 12.0% 
Stage 4 15,445 34.6% 1,779 27.7% 
Stage 5 2,937 59.1% 317 51.7% 
* Based on last eGFR measurement. Stage 3a: eGFR 46-59ml/min/1.73m2; stage 3b: eGFR 31-
45ml/min/1.73m2; stage 4: eGFR 16-30ml/min/1.73m2; stage 5: eGFR<15ml/min/1.73m2 
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Table 3 Coding improvement amongst those with biochemical evidence of CKD at round 1 
(uncoded) and round 2 of the National CKD Audit 
 N with biochemical 
evidence of CKD at R1 
(uncoded) and R2 
% of these 
coded at R2 
 
Multivariable** OR for 
coding improvement at 
R2 
Sex 
     Female 
     Male 
 
32,661 
21,339 
 
9.0% 
10.7% 
 
1 
1.14 (1.09, 1.19) 
Age 
     <50 
     50-59 
     60-69 
     70-79 
     80-89 
     90+ 
 
1,507 
3,636 
10,243 
17,844 
16,537 
4,233 
 
8.2% 
7.5% 
9.7% 
10.4% 
9.6% 
9.2% 
 
0.83 (0.72, 0.97) 
0.85 (0.78, 0.94) 
1 
1.04 (0.99, 1.10) 
0.96 (0.90, 1.02) 
0.86 (0.79, 0.95) 
IMD$ 
     <10000 
     10000-14999 
     15000-19999 
     20000-24999 
     25000+ 
     Missing 
 
7,481 
5,286 
5,816 
6,514 
8,088 
20,815 
 
11.7% 
11.8% 
13.0% 
10.8% 
10.9% 
6.6% 
 
1 
1.01 (0.92, 1.12) 
0.97 (0.87, 1.07) 
0.93 (0.85, 1.02) 
0.94 (0.87, 1.03) 
0.85 (0.63, 1.16) 
Last known CKD stage* 
     Stage 3a  
     Stage 3b  
     Stage 4  
     Stage 5  
 
42,405 
10,085 
1,302 
208 
 
8.7% 
12.5% 
16.9% 
13.9% 
 
1 
1.50 (1.42, 1.59) 
2.02 (1.78, 2.30) 
1.53 (1.08, 2.17) 
Diabetes status 
     No 
     Yes 
 
41,934 
12,066 
 
9.0% 
11.8% 
 
1 
1.21 (1.15, 1.28) 
Hypertension status 
     No 
     Yes 
 
20,784 
33,216 
 
8.1% 
10.6% 
 
1 
1.24 (1.17, 1.31) 
Statin offered 
     No 
     Yes 
 
21,850 
32,150 
 
8.8% 
10.2% 
 
1 
1.08 (1.03 1.13) 
Country 
     Wales 
     England 
 
20,917 
33,083 
 
6.7% 
11.5% 
 
1 
1.21 (0.81, 1.79) 
* based on last eGFR measurement at R1. Stage 3a: eGFR 46-59ml/min/1.73m2; stage 3b: eGFR 31-
45ml/min/1.73m2; stage 4: eGFR 16-30ml/min/1.73m2; stage 5: eGFR<15ml/min/1.73m2 
** simultaneous adjustment for all characteristics in table 
R1 = round 1; R2 = round 2 
$ Low IMD rank corresponds to higher deprivation 
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Table 4  Management outcomes for those with biochemical evidence of CKD at round 1, by 
coding status 
 
 Coded CKD Uncoded CKD with 
renal disorder code 
Uncoded CKD without 
renal disorder code 
N 178,277 6,176 71,980 
    
Met blood pressure target 
in past year* 
   
     % achieving outcome 51.5% 41.7% 46.8% 
     Adjusted OR (95% CI)$ 1 0.83 (0.78, 0.87) 0.78 (0.76, 0.79) 
Statins offered    
     % achieving outcome 70.5% 69.2% 57.8% 
     Adjusted OR (95% CI)$$ 1 1.04 (0.97, 1.11) 0.69 (0.67, 0.71) 
ACR/PCR test in past year    
     % achieving outcome 49.7% 32.7% 15.9% 
     Adjusted OR (95% CI)$$$ 1 0.50 (0.45, 0.55) 0.20 (0.18, 0.22) 
ACR/PCR test in past 2 
years 
   
     % achieving outcome 73.8% 49.4% 25.1% 
     Adjusted OR (95% CI)$$$ 1 0.35 (0.32, 0.39) 0.12 (0.11, 0.13) 
Flu vaccination in past 
year 
   
     % achieving outcome 79.3% 72.9% 69.6% 
     Adjusted OR (95% CI)$ 1 0.83 (0.77, 0.88) 0.75 (0.73, 0.77) 
Pneumococcus vaccination 
in past 5 years, stage 4-5 
only (based on last eGFR)^ 
   
     % achieving outcome 16.1% 15.5% 11.3% 
     Adjusted OR (95% CI)$ 1 0.79 (0.63, 1.00) 0.73 (0.62, 0.86) 
* measurements taken in past year and sbp<130mmHg and dbp<80mmHg (for those with diabetes or 
proteinuria) or sbp<140mmHg and dbp<90mmHg for everyone else 
$ adjusted for IMD group, sex, age group, country, last known CKD stage, diabetes, hypertension, CVD and 
statins offered.  
$$ adjusted for sex, age group, last known CKD stage, hypertension and CVD (due to model convergence).  
$$$ adjusted for age group and last known CKD stage only (due to model convergence).  
^ numbers in stage 4-5 in each coding category: coded CKD (n=19,076), uncoded CKD with renal code (n=755), 
uncoded CKD without renal code (n=1,739) 
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